H. Lundbeck AS (LTS:0ABR) Short Ratio

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LTS:0ABR H. Lundbeck AS LTS:0ABR
77 GF Score
Price kr36.30
GF Value kr38.17
Valuation Fairly Valued
! 3 Warning Signs
View Full Analysis

What is H. Lundbeck AS Short Ratio?

Short Ratio is a metric signaling prevailing investors' sentiment with a company. It represents the number of days it takes short sellers on average to repurchase all the shares short.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

LTS:0ABR
77GF Score
H. Lundbeck AS LTS:0ABR
Short Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is H. Lundbeck AS (LTS:0ABR) Overvalued in 2026?

Based on GuruFocus' analysis, H. Lundbeck AS stock appears to be undervalued. The current stock price of kr36.30 is trading 4.9% below its estimated GF Value™ of kr38.17. GuruFocus considers H. Lundbeck AS to be Fairly Valued.

Key valuation signals for LTS:0ABR:

  • Short Ratio:
  • GF Value™: kr38.17 vs. price of kr36.30 (4.9% below fair value)
  • GF Score™: 77/100 with 3 warning signs

No single metric tells the full story. See the LTS:0ABR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

H. Lundbeck AS Business Description

Address Ottiliavej 9, Valby, DNK, 2500
Lundbeck is a Denmark-based pharmaceutical firm that focuses on the development and commercialization of central nervous system drugs including antidepressants, antipsychotics, and antiepileptic products. The company's portfolio includes Abilify Maintena and Rexulti for psychosis, Brintellix/Trintellix for depression, Northera for Parkinson's disease symptoms, Sabril and Onfi for seizures, and Vyepti for migraine prevention. Most of the company's sales are derived in North America, followed by Asia and Europe.
77GF Score

Get the complete analysis for LTS:0ABR

Short Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr36.30
Price
kr38.17
GF Value